We value: Our readers.
Our independence. Our region.
The power of real journalism.
We're reader supported.
Get our newsletter free.
Help pay for our reporting.
Analysis
  |  
Health
  |  
Coronavirus

We’re Getting a Better Picture of the Lambda Variant

It’s contributed to a higher mortality rate in Peru. But mRNA vaccines will probably remain protective against it.

Tara Hurst 13 Jul 2021 | The Conversation

Tara Hurst is a lecturer in biomedical science at Birmingham City University. This article was originally published in the Conversation. Read the original article here.

Peru has the highest number of COVID-19 deaths per capita, by far. For every 100,000 Peruvians, 596 have died of COVID. This is almost double the next hardest-hit country, Hungary, which has 307 deaths per 100,000 people.

There are many reasons Peru has fared so badly in the pandemic. They include a poorly funded, under-prepared health-care system with too few ICU beds; slow vaccine rollout; limited testing capacity; a large informal economy that meant few people could afford to miss work; and overcrowded housing.

The country was also beset by the Lambda variant.

Initially reported in Lima in August 2020, by April 2021 the Lambda variant accounted for 97 per cent of all sequences in Peru.

Lambda has now gone globetrotting. According to a recent World Health Organization report, it has been found in 29 countries. “Lambda has been associated with substantive rates of community transmission in multiple countries,” the report finds, “with rising prevalence over time concurrent with increased COVID-19 incidence.”

On June 14, 2021, WHO declared Lambda a “global variant of interest.” Public Health England followed suit on June 23, designating it a “variant under investigation” because of its “international expansion and several notable mutations.”

Of the eight confirmed cases of Lambda in the U.K., most have been linked to overseas travel.

What the evidence shows

A variant of interest is one that has mutations that are predicted or known to affect things such as transmissibility (how easily the virus spreads), severity of disease, ability to evade immunity from past infections or vaccines, or confound diagnostic tests.

Many scientists speak of Lambda’s “unusual combination” of mutations, which may make it more transmissible.

Lambda has seven mutations on the spike protein, the mushroom-shaped projections on the outer shell of the virus that help it latch onto our cells and invade them. These mutations may make it easier for Lambda to bind to our cells and make it harder for our antibodies to latch onto the virus and neutralize it.

Jim Freeman, vice-president of Research and Development Laboratory Diagnostics at Siemens Healthineers, explains what spike proteins are and how they impact the development of antibody tests.

But it’s important to remember that neutralizing antibodies aren’t the only tool in the immune system’s toolkit — they are merely the easiest to study. T cells play a vital role too, so a handful of mutations, however unusual, might not be enough to allow Lambda to dodge our immune system altogether.

So what evidence do we have that these mutations make Lambda more dangerous than the original coronavirus? Very little, it turns out.

There are no published studies on the Lambda variant and just a handful of preprints — papers that have yet to be subject to the peer review process or published in a journal.

A preprint from the New York University Grossman School of Medicine looked at the effect of the Pfizer and Moderna vaccines against the Lambda variant and found a two-to-threefold reduction in vaccine-elicited antibodies compared with the original virus. In the scheme of things, this is not a massive loss of neutralizing antibodies. The researchers conclude that these mRNA vaccines will probably remain protective against the Lambda variant.

Researchers from the University of Chile investigated the effect of the Sinovac (also known as “CoronaVac”) vaccine against the Lambda variant. They also found a threefold reduction in neutralizing antibodies compared with the original variant.

The fact that these two studies found that neutralization is at least partially retained is promising, not least because this is only one facet of the immune response elicited by vaccination.

According to PHE’s most recent Lambda risk assessment, released July 8, there is no evidence of a country where Lambda has outcompeted Delta. Studies are ongoing, but for now, Lambda remains a variant of interest rather than a variant of concern.The Conversation  [Tyee]

Read more: Health, Coronavirus

Share this article

The Tyee is supported by readers like you

Join us and grow independent media in Canada

Facts matter. Get The Tyee's in-depth journalism delivered to your inbox for free.

Tyee Commenting Guidelines

Comments that violate guidelines risk being deleted, and violations may result in a temporary or permanent user ban. Maintain the spirit of good conversation to stay in the discussion.
*Please note The Tyee is not a forum for spreading misinformation about COVID-19, denying its existence or minimizing its risk to public health.

Do:

  • Be thoughtful about how your words may affect the communities you are addressing. Language matters
  • Challenge arguments, not commenters
  • Flag trolls and guideline violations
  • Treat all with respect and curiosity, learn from differences of opinion
  • Verify facts, debunk rumours, point out logical fallacies
  • Add context and background
  • Note typos and reporting blind spots
  • Stay on topic

Do not:

  • Use sexist, classist, racist, homophobic or transphobic language
  • Ridicule, misgender, bully, threaten, name call, troll or wish harm on others
  • Personally attack authors or contributors
  • Spread misinformation or perpetuate conspiracies
  • Libel, defame or publish falsehoods
  • Attempt to guess other commenters’ real-life identities
  • Post links without providing context

LATEST STORIES

The Barometer

Tyee Poll: Have We Seen the Worst Heat Wave of the Summer?

Take this week's poll